Arcutis Biotherapeutics (NASDAQ: ARQT) director sells 1,072 shares
Rhea-AI Filing Summary
Arcutis Biotherapeutics, Inc. (ARQT) director Terrie Curran reported an option exercise-and-sale sequence. Curran exercised a stock option for 1,072 shares of common stock at an exercise price of $7.51 per share, then sold 1,072 shares of common stock at a weighted average sale price of $26.0376 per share in multiple trades between $26.00 and $26.2228. After the derivative transaction, Curran held 11,148 stock options directly, with the option described as fully vested and expiring on May 31, 2033.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 1,072 shares ($20K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Curran Terrie
Role
Director
Sold
1,072 shs ($28K)
Approx. gross sale proceeds
$28K
Approx. exercise cost
$8K
Approx. pre-tax spread
$20K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F3 | 1,072 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,072 | $7.51 | $8K |
| Sale | Common Stock F1, F2 | 1,072 | $26.0376 | $28K |
Holdings After Transaction:
Stock Option (right to buy) — 11,148 shares (Direct);
Common Stock — 23,526 shares (Direct)
Footnotes (3)
- F1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
- F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. The option is fully vested.
Key Figures
Options exercised: 1,072 shares
Option exercise price: $7.51 per share
Shares sold: 1,072 shares
+3 more
6 metrics
Options exercised
1,072 shares
Stock option for common stock exercised on August 20, 2026
Option exercise price
$7.51 per share
Exercise price of stock option converted into common stock
Shares sold
1,072 shares
Common stock sold on August 20, 2026
Weighted average sale price
$26.0376 per share
Weighted average price for sales between $26.00 and $26.2228
Remaining stock options
11,148 options
Total options held directly following the derivative transaction
Option expiration date
May 31, 2033
Expiration date of the exercised stock option
Key Terms
Stock Option (right to buy), weighted average sale price, Exercise or conversion of derivative security, non-employee director
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
weighted average sale price financial
"The price reported in Column 4 is a weighted average sale price."
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
non-employee director financial
"subject to the non-employee director's continuous service."
FAQ
What insider transaction did ARQT director Terrie Curran report on August 20, 2026?
Terrie Curran reported exercising a stock option for 1,072 shares of Arcutis Biotherapeutics common stock at $7.51 per share and selling 1,072 shares at a weighted average price of $26.0376 per share on August 20, 2026.
What is the exercise price and expiration date of Terrie Curran’s ARQT stock option?
The stock option exercised by Terrie Curran had an exercise price of $7.51 per share and an expiration date of May 31, 2033. The option is reported as fully vested.
How many ARQT stock options does Terrie Curran hold after the reported transaction?
Following the reported derivative transaction, Terrie Curran held 11,148 stock options for Arcutis Biotherapeutics common stock directly, as disclosed in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
